StoneX Group’s Adverum Biotechnologies ADVM Stock Holding History

StoneX Group’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,483	Closed	-$17.8K	–	357
2022 Q2	$17.8K	Buy	+1,483	New	+$15.5K	﹤0.01%	440

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

StoneX Group's ADVM Position: Q3 2022 in Review

StoneX Group sold out of Adverum Biotechnologies (ADVM) in Q3 2022, closing a stake of 1,483 shares — an estimated $17.8K sold.

StoneX Group first reported a position in ADVM in Q2 2022 and held it in 1 quarter. The position peaked at $17.8K in Q2 2022. 78 funds tracked by Wall St. Rank hold ADVM as of Q3 2022.

StoneX Group reported no remaining Adverum Biotechnologies position as of Q3 2022 after selling out during the quarter.
StoneX Group sold 1,483 Adverum Biotechnologies shares in Q3 2022, an estimated $17.8K.
StoneX Group first reported a position in Adverum Biotechnologies in Q2 2022 and held it in 1 quarter.
StoneX Group's Adverum Biotechnologies position peaked at $17.8K in Q2 2022.
78 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.